Understanding Nonketotic Hyperglycinemia
A rare inherited disorder of glycine breakdown that leads to a toxic buildup of glycine in the brain and spinal fluid, causing severe neurological symptoms in most affected infants. Supportive and medical management can reduce seizure burden and improve comfort.
- Autosomal Recessive Inheritance
- Caused by Glycine Cleavage Enzyme Defects
- Managed with Specialist Neurometabolic Care
- Estimated Incidence
- 1 in 60,000 births (higher in some populations)
- Inheritance Pattern
- Autosomal Recessive
- Genes Involved
- GLDC, AMT
- Typical Onset
- First Days of Life
- Specialist Access
- Neurometabolic Genetics Coordination
Condition Overview
Nonketotic hyperglycinemia (NKH), also called glycine encephalopathy, is a rare inherited disorder caused by a defect in the glycine cleavage enzyme system, most often due to mutations in the GLDC or AMT genes. This leads to abnormally high levels of glycine in the blood, urine, and especially the cerebrospinal fluid, which is toxic to the developing brain.
The classic neonatal form presents in the first days of life with severe encephalopathy, while milder infantile and atypical forms exist with later onset and somewhat less severe symptoms.
Types and Variants
Nonketotic hyperglycinemia presents along a spectrum of severity and age of onset.
Symptoms and Signs
Symptoms in the classic form typically begin within the first days of life and progress rapidly without treatment.
Causes and Risk Factors
Nonketotic hyperglycinemia results from inherited mutations affecting the glycine cleavage enzyme system.
Diagnosis and Investigations
Diagnosis relies on biochemical testing of glycine levels, supported by genetic confirmation.
Severity Classification
Nonketotic hyperglycinemia is classified by age of onset and clinical severity rather than a cancer-style staging system.
Standard Management
There is no cure for nonketotic hyperglycinemia. Treatment focuses on reducing glycine-related neurotoxicity and managing seizures and supportive needs.
Emerging Approaches and Research
Research continues into therapies that may further reduce glycine-related brain injury.
Pharmacological Research
Investigational Glycine Transporter Inhibitors
Early-stage research is exploring agents that block glycine transport as a way to further reduce central nervous system glycine levels.
Gene Therapy Research
Investigational Gene-Targeted Approaches
Preclinical research is exploring gene-based strategies aimed at restoring glycine cleavage enzyme function.
Biomarkers & Laboratory Monitoring
Biochemical glycine measurements are central to both diagnosis and ongoing monitoring.
When to Seek a Second Opinion
Given the complexity and severity of nonketotic hyperglycinemia, families may benefit from additional specialist input.
Research and Clinical Studies
Prognosis & Outlook
Prognosis varies considerably depending on the form of the disease and degree of residual enzyme function.
Supportive Care
Comprehensive supportive care addresses the significant neurological and caregiving needs associated with this condition.
How CancerFax Helps You Explore Treatment Options
CancerFax can help families review medical and genetic reports and connect with neurometabolic specialists experienced in nonketotic hyperglycinemia.
Get a free case reviewFrequently Asked Questions
Nonketotic hyperglycinemia, also called glycine encephalopathy, is a rare inherited disorder caused by a defective glycine cleavage enzyme system, leading to toxic glycine buildup in the brain.
In the classic form, signs typically begin within the first days of life, including lethargy, low muscle tone, abnormal movements, and seizures.
It is most often caused by mutations in the GLDC gene, and less commonly the AMT gene, inherited in an autosomal recessive pattern.
Diagnosis relies on an elevated cerebrospinal fluid to plasma glycine ratio, supported by genetic testing of the GLDC and AMT genes.
There is no cure; treatment with sodium benzoate and NMDA receptor-modulating medications aims to reduce glycine toxicity and manage seizures.
Yes, it is inherited in an autosomal recessive pattern, meaning both parents typically carry one copy of an altered gene.
The outlook varies widely; the classic severe neonatal form is generally associated with significant neurological impairment, while milder or transient forms may have better outcomes.
Yes, seizures are common, particularly in the classic neonatal form, and can be difficult to fully control.
Seek immediate medical evaluation, as lethargy, abnormal movements, or apnea in a newborn require urgent assessment.
Yes, CancerFax can assist with medical report review, second opinions, and coordination with neurometabolic specialists, including international referral support where relevant.
Need Guidance on a Nonketotic Hyperglycinemia Diagnosis?
CancerFax can help you review medical reports and connect with neurometabolic specialists for further evaluation.